Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context

Journal of Molecular Recognition

Volumn 13, Issue 3, 2000, Pages 127-139

  Ben Khalifa, Myriam ^a   Weidenhaupt, Marianne ^a   Choulier, Laurence ^b   Chatellier, Jean ^d   Rauffer Bruyère, Nathalie ^b   Altschuh, Danièle ^b   Vernet, Thierry ^a,c  

^a CNRS   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antibody engineering; Biacore ; Kinetic rate constants; Peptide antibody interaction; Recombinant Fab; Site directed mutagenesis; VH VL interface

Indexed keywords

AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BINDING KINETICS; FAB FRAGMENT; MUTANT; MUTATION;

AMINO ACID SEQUENCE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; MOSAIC VIRUSES; MUTAGENESIS; MUTATION; PAPILLOMAVIRIDAE; VIRAL PROTEINS;

EID: 0004773096     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1352(200005/06)13:3<127::AID-JMR495>3.0.CO;2-9     Document Type: Article

References (37)

1. Alfthan K, Takkinen K, Sizmann D, Seppala I, Immonen T, Vanne L, Keranen S, Kaartinen M, Knowles JK, Teeri TT. 1993. Efficient secretion of murine Fab fragments by Escherichia coli is determined by the first constant domain of the heavy chain. Gene. 128: 203-209.
2. Al Moudallal Z, Briand JP, Van Regenmortel MHV. 1985. A major part of the polypeptide chain of tobacco mosaic virus protein is antigenic. EMBO J. 4: 1231-1235.
3. Baca M, Presta LG, O'Connor SJ, Wells JA. 1997. Antibody humanization using monovalent phage display. J. Biol. Chem. 272: 10678-10684.
4. Barbas CFd, Languino LR, Smith JW. 1993. High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. Proc. Natl Acad. Sci. USA 90: 10003-10007.
5. Chatellier J, Rauffer-Bruyère N, Van Regenmortel MH, Altschuh D, Weiss E. 1996a. Comparative interaction kinetics of two recombinant Fabs and of the corresponding antibodies directed to the coat protein of tobacco mosaic virus. J. Mol. Recognit. 9: 39-51X.
6. Chatellier J, Van Regenmortel MH, Vernet T, Altschuh D. 1996b. Functional mapping of conserved residues located at the VL and VH domain interface of a Fab. J. Mol. Biol. 264: 1-6X.
7. Cheetham GM, Hale G, Waldmann H, Bloomer AC. 1998. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J. Mol. Biol. 284: 85-99.
8. Chien NC, Roberts VA, Giusti AM, Scharff MD, Getzoff ED. 1989. Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism. Proc. Natl Acad. Sci. USA 86: 5532-5536.
9. Chothia C, Gelfand I, Kister A. 1998. Structural determinants in the sequences of immunoglobulin variable domain. J. Mol. Biol. 278: 457-479.
10. Choulier L, Rauffer-Bruyère N, Ben Khalifa M, Martin F, Vernet T, Altschuh D. 1999. Kinetic analysis of the effect on Fab binding of identical substitutions in a peptide and its parent protein. Biochemistry 38: 3530-3537.
11. Chowdhury PS, Vasmatzis G, Beers R, Lee B, Pastan I. 1998. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. (In Process Citation.) J. Mol. Biol. 281: 917-928.
12. England P, Nageotte R, Renard M, Page AL, Bedouelle H. 1999. Functional characterization of the somatic hypermutation process leading to antibody D1.3, a high affinity antibody directed against lysozyme. J. Immunol. 162: 2129-2136.
13. Foote J, Winter G. 1992. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224: 487-499.
14. Gelfand IM, Kister AE. 1995. Analysis of the relation between the sequence and secondary and three- dimensional structures of immunoglobulin molecules. Proc. Natl Acad. Sci. USA 92: 10884-10888.
15. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77: 51-59.
16. Horovitz A. 1996. Double-mutant cycles: a powerful tool for analyzing protein structure and function. Fold Des. 1: R121-R126.
17. Huibregtse JM, Beaudenon SL 1996. Mechanism of HPV E6 proteins in cellular transformation. Sem. Cancer Biol. 7: 317-326.
18. Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS, Foeller C. 1991. Sequences of Proteins of Immunological Interest. 5th edn, Department of Health and Human Services, Bethesda, MD.
19. Koshi JM, Goldstein RA. 1997. Mutation matrices and physical-chemical properties: correlations and implications. Proteins 27: 336-344.
20. Kunkel TA. 1985. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl Acad. Sci. USA 82: 488-492.
21. LiCata VJ, Ackers GK. 1995. Long-range, small magnitude nonadditivity of mutational effects in proteins. Biochemistry 34: 3133-3139.
22. Lortat-Jacob H, Ricard-Blum S. 1997. Use of plasmon resonance (BIAcore™) for the analysis of ligand-receptor interactions. In Visualization of receptors - Methods in Light and Electron Microscopy CRC Press, Boca Raton, FL (Morel, G., ed.), pp. 161-180.
23. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. 1992. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (NY) 10: 779-783X.
24. Ohtomo T, Tsuchiya M, Sato K, Shimizu K, Moriuchi S, Miyao Y, Akimoto T, Akamatsu K, Hayakawa T, Ohsugi Y. 1995. Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. Mol. Immunol. 32: 407-416.
25. Orfanoudakis G, Karim B, Bourel D, Weiss E. 1993. Bacterially expressed Fabs of monoclonal antibodies neutralizing tumour necrosis factor alpha in vitro retain full binding and biological activity. Mol. Immunol. 30: 1519-1528.
26. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. 1993. Humanization of an antibody directed against IgE. J. Immunol. 151: 2623-2632.
27. Rauffer-Bruyère N, Chatellier J, Weiss E, Van Regenmortel MH, Altschuh D. 1997. Cooperative effects of mutations in a recombinant Fab on the kinetics of antigen binding. Mol. Immunol. 34: 165-73X.
28. Richalet-Secordel PM, Rauffer-Bruyere N, Christensen LL, Ofenloch-Haehnle B, Seidel C, Van Regenmortel MH. 1997. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal. Biochem. 249: 165-173.
29. Roguska MA, Pedersen JT, Henry AH, Searle SM, Roja CM, Avery B, Hoffee M, Cook S, Lambert JM, Blattler WA, Rees AR, Guild BC. 1996. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. [Published erratum appears in Protein Engn 1997; 10(2): 181.] Protein Engng. 9: 895-904.
30. Sandberg WS, Terwilliger TC. 1993. Engineering multiple properties of a protein by combinatorial mutagenesis. Proc. Natl Acad. Sci. USA 90: 8367-8371.
31. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. 1996. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263: 551-567.
32. Schreiber G, Fersht AR. 1995. Energetics of protein-protein interactions: analysis of the barnase-barstar interface by single mutations and double mutant cycles. J. Mol. Biol. 248: 478-486.
33. Sharon J. 1990. Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p- azophenylarsonate antibody 200-fold. Proc. Natl Acad. Sci. USA 87: 4814-4817.
34. Tan PH, Sandmaier BM, Stayton PS. 1998. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys. J. 75: 1473-1482.
35. Xiang J, Sha Y, Jia Z, Prasad L, Delbaere LT. 1995. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. J. Mol. Biol. 253: 385-390.
36. Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF III. 1995. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254: 392-403.
37. Yanisch-Perron C, Vieira J, Messing J. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33: 103-119.